Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Anti-D Immunoglobulin Market Size, Value And Growth Trajectory Through 2030
The anti-d immunoglobulin market has shown substantial expansion in recent years. Its valuation is anticipated to rise from $2.59 billion in 2025 to $2.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. Over the historical period, this growth can be ascribed to a number of factors including limited plasma donor pools, reliance on manual antibody extraction processes, increasing awareness of hemolytic disease, expanding usage in hospitals and clinical settings, and the adoption of intramuscular administration.
The anti-d immunoglobulin market is projected to show significant expansion in the upcoming years. It is forecast to reach $3.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period can be attributed to the development of intravenous formulations, the wider adoption of automated plasma fractionation technologies, a rise in antenatal screening programs, the increasing global blood bank infrastructure, and the expansion of personalized immunoglobulin therapies. Prominent trends for this period include a growing demand for anti-d immunoglobulin in the management of hemolytic disease, an increased preference for pre-filled syringes and single-use vials, the broadening of antenatal and postnatal prophylaxis programs, the growth of distribution channels based in hospitals and blood banks, and an enhanced focus on ensuring safety, purity, and regulatory compliance.
Get A Free Sample Report With In-Depth Market Insights:
Anti-D Immunoglobulin Market Growth Factors Behind Sustained Expansion
The anti-D immunoglobulin market is projected to expand driven by increasing birth rates. These rates, defined as annual live births per 1,000 individuals, are rising partly due to limited access to education and family planning, leading to higher fertility and larger family sizes. Anti-D immunoglobulin plays a crucial role by mitigating Rh incompatibility during pregnancy, thereby lowering the risk of hemolytic disease in newborns and fostering healthier subsequent pregnancies. For example, data from the US-based Centers for Disease Control and Prevention indicated 3,622,673 births in 2024, a 1% rise from the previous year, highlighting this trend. Consequently, elevated birth rates are a key factor boosting the anti-D immunoglobulin market.
Anti-D Immunoglobulin Market Driver: Expansion Of Healthcare Infrastructure Fueling The Growth Of The Market Due To Improved Access To Maternal Care Services
The anti-D immunoglobulin market is set to grow as healthcare infrastructure continues to expand. This infrastructure, encompassing facilities, equipment, personnel, and support systems for medical services, is developing in response to increasing global populations, which in turn elevates the demand for healthcare and necessitates more hospitals, clinics, and related resources. Such expansion improves access to maternal care, facilitating superior screening and prompt administration of anti-D immunoglobulin to avert hemolytic disease in newborns. For instance, in May 2023, the UK’s Department of Health and Social Care declared plans to invest over $27 billion (£20 billion) in new hospital construction, with two hospitals already finished, five underway, and over 20 projected to be in progress or completed by the end of 2023 under the New Hospital Programme. This expansion of healthcare infrastructure is thus a key driver for the anti-D immunoglobulin market.
Anti-D Immunoglobulin Market Segment Landscape And Growth Outlook
The anti-d immunoglobulin market covered in this report is segmented –
1) By Product Type: Intramuscular Anti-D Immunoglobulin, Intravenous Anti-D Immunoglobulin
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channel
3) By Application: Hemolytic Disease Of The Newborn, Immune Thrombocytopenic Purpura, Antenatal And Postnatal Prophylaxis, Other Applications
4) By End-User: Hospitals, Clinics, Blood Banks, Research Laboratories
Subsegments:
1) By Intramuscular Anti-D Immunoglobulin: Standard Dose, High Dose, Pre-Filled Syringes, Vials
2) By Intravenous Anti-D Immunoglobulin: Lyophilized Powder, Liquid Formulation, Single-Use Vials, Multi-Dose Vials
Anti-D Immunoglobulin Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the anti-d immunoglobulin market are CSL Behring, Octapharma AG, Kedrion Biopharma Inc., Biotest AG, Sanquin, Bharat Serums and Vaccines Limited, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Emergent BioSolutions Inc., Kamada Pharmaceuticals, Saol Therapeutics Inc., Avin Darou, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Taj Pharmaceuticals Limited, Aetos Pharma Private Limited, PV Pharma Healthcare Pvt. Ltd., Grifols S.A., Takeda Pharmaceutical Company Limited, LFB Biomedicaments, China Biologic Products Holdings Inc., Shanghai RAAS Blood Products Co. Ltd., Hualan Biological Engineering Inc., CBPO (Shandong Taibang Biological Products Co. Ltd.), Bio Products Laboratory (BPL), Instituto Grifols S.A., HemaCare Corporation, KM Biologics Co. Ltd., National Bioproducts Institute (NBI), GC Pharma (Green Cross Corporation), SK Plasma Co. Ltd.
View The Full Anti-D Immunoglobulin Market Report:
Anti-D Immunoglobulin Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the anti-D immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-d immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model